Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

By | August 28, 2021
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.